Fisher Scientific adds cell line to stem cell research portfolio

Thermo Fisher Scientific adds cell line to stem cell research portfolio

Thermo Fisher Scientific has introduced its Multipotent Cord Blood Unrestricted Somatic Stem Cells from Cellular Engineering Technologies (CET).

These stem cells are designed to be utilised in a number of research applications including the cultivation of neural-like cells, the study of blood development and research of liver disease and cardiac failure.

According to the company, Multipotent Cord Blood Unrestricted Somatic Stem Cells have the potential to differentiate into neural-like cells and osteocytes (nerve cells and bone cells).

They are isolated from human umbilical cord blood using differential plating techniques and a proprietary media formulation – enabling them to be used for research into neurological diseases such as Parkinson’s.

Via an agreement with CET, Thermo Fisher Scientific is now marketing the stem cells worldwide as a complementary offering to its differentiation kits.

Meanwhile, in related news, the Wall Street Journal reports that Thermo Fisher Scientific topped the list for selling on strength which tracks stocks that rose in price but had the largest outflow of money.